Asia-Pacific schizophrenia drugs market is projected to grow at a significant CAGR of 3.6% during the forecast period (2020-2026). In Asia-Pacific, the schizophrenia has a high prevalence in South Asian countries as compared to the rest of the region. According to the Progress in Mind, there are significantly different medication patterns preferred across South Asian countries.
- 42% of patients were prescribed more than 1 antipsychotic; however, polypharmacy rates ranged from 59% in Vietnam to 22% in Myanmar.
- Anxiolytics (Pakistan 56% compared to Myanmar 9%)
- Hypnotics (Japan 61% compared to Sri Lanka and Myanmar 0%)
- Anti-Parkinsonian drugs (Bangladesh 88% compared to Vietnam 11%)
To Request a Sample of our Report on Asia-Pacific Schizophrenia Drugs Market: https://www.omrglobal.com/request-sample/asia-pacific-schizophrenia-drugs-market
The presence of huge population and gender inequality in the South Asian economies, such as Pakistan and India, has been the major factor for the rising demand for schizophrenia drugs in these economies. Along with this, the increasing awareness about mental health in the emerging South Asian economies, such as India and Vietnam, the schizophrenia drug industry is continuously increasing and driving the Asia-Pacific schizophrenia drug market. There are several mental health organizations and hospitals being established in the last decade and the trend is expected to continue during the forecast period.
(Get 15% Discount on Buying this Report)
A full Report of Asia-Pacific Schizophrenia Drugs Market is Available at: https://www.omrglobal.com/industry-reports/asia-pacific-schizophrenia-drugs-market
Key questions addressed by the report
- What is the market growth rate during the forecast period?
- Which segment/region dominates the market in the base year?
- Which segment/region will project the fastest growth in the market during the forecast period?
- How COVID-19 will impact the market growth in 2020 and coming years?
- Recovery Timeline
- Deviation from pre-COVID-19
- Most affected region/segment
- Recommendations
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Asia-Pacific Schizophrenia Drugs Market – Segmentation
By Therapeutic Class
- Second Generation Antipsychotics
- Third Generation Antipsychotics
- Others (First Generation Antipsychotics)
By Treatment
- Oral
- Injectables
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
